News

According to the company, duloxetine-treated patients showed greater reductions from baseline on the primary endpoint, the 24-hour average pain score on the Brief Pain Inventory (BPI), compared with

According to the company, Advance PTX is one of the first PTA balloon catheters to be coated with paclitaxel, an antiproliferative drug that has been used successfully to

The 360 patient, active comparator trial compared the efficacy and safety of NP-1 against both gabapentin and placebo. The first primary endpoint was the change in pain intensity

The investors have agreed to purchase the shares at a purchase price of $9.73 per share resulting in gross proceeds of approximately $45.5 million to Pharmasset, before deducting

Terrance Gregg, DexCom’s president and CEO, is also purchasing 150,000 additional shares of common stock in this offering at a price per share of $3.12, which represents the

Under the transaction, Exact retained exclusive worldwide rights to its colorectal cancer screening and stool-based DNA testing intellectual property, and will receive a share of Genzyme’s sublicensing income

As the first company to file an abbreviated new drug application containing a paragraph IV certification for this product, Teva has received a 180-day period of marketing exclusivity.

QuantRx expects that the product will be launched by Church & Dwight under its First Response brand and will be available at the retail level in the second

Highlights Total operating expenses increased $2,225 or less than 1% vs. the prior year’s comparable quarter. Operating loss for the quarter was $61,060 vs. $62,913 for the prior